Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Albiglutide: Phase III data

The open-label, international Phase III Harmony 4 trial in 735 Type II diabetics who were inadequately controlled on metformin with or without a sulfonylurea showed that once-weekly subcutaneous 30 mg albiglutide met the

Read the full 335 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE